The data shows that immune cells converge at sites of motor neuron loss and TDP-43 pathology with distinct patterns depending on the ALS type.

The CEO of Caszyme, a biotech company in Vilnius, Lithuania, presented details of Cas12l, a novel compact Cas nuclease with a ...

The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...

BOSTON – The CEO of the American Society for Gene and Cell Therapy (ASGCT), David Barrett, JD, presented highlights from the Society’s latest Landscape Report on Cell, Gene and RNA Therapy for the ...

The new CRISPR platform, called ΨDNA, reprograms Cas12 nucleases to recognize and act on RNA using a DNA-based guide scaffold ...

When these anchors are attached to cancer drugs, they attach to cell membranes and shrink tumors better than unmodified drug ...

These “living therapeutics” can sustain themselves in vivo and survive in biological environments including tumors, inflamed ...

Bristol Myers Squibb (BMS) will partner with Hengrui Pharma to co-develop 13 early-stage programs in oncology, hematology, ...

Researchers at the University of Pennsylvania developed ApexGO, an AI-powered system that optimizes antimicrobial peptides.

Researchers say findings may have relevance to understanding cell biological pathways that contribute to nerve repair after injury or neurodegeneration.

One of the winners of the 2026 ASGCT Catalyst Award, Kiran Musunuru, MD, PhD, delivered a sobering lecture on the legacy of ...

Sickle cell warrior Victoria Gray, the first patient to enroll in the Casgevy gene editing trial, shared some highs and lows ...